GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma completes transfer of domestic branded generics business to Auropharm

M&A ● No Immediate Change LOW RISK
📅 Filed on BSE: 02 Jul 2026, 10:38 AM IST  ·  BSE ID: f068d1f5-768c-4d33-bf69-90ebd4175133
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma has finished moving its India-specific branded medicine business to its subsidiary, Auropharm.
🤖 AI Summary
  • Aurobindo Pharma completed transfer of domestic branded generic formulations business to Auropharm Limited.
  • The business transfer to wholly-owned subsidiary Auropharm Limited became effective from July 1, 2026.
  • The transfer was executed as a going concern on a slump sale basis under a Business Transfer Agreement.
  • This completion follows an initial intimation by Aurobindo Pharma dated April 6, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Transfer consideration (as per April 6, 2026 filing)
INR 143.21 Crores
🏢 How This Affects the Company
📈
Business Impact
This formalizes the operational separation of Aurobindo Pharma's domestic branded generic pharmaceutical formulations products business into a dedicated subsidiary, Auropharm Limited.
💰
Financial Impact
The financial impact stems from the previously disclosed transfer value of INR 143.21 Crores for this business segment to Auropharm Limited.
⚙️
Operational Impact
Auropharm Limited now solely undertakes the domestic branded generic pharmaceutical formulations products business, effective July 1, 2026, streamlining operations.
⚠️
Risk Impact
This internal restructuring may lead to a clearer operational focus for both the parent company and its specialized subsidiary.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this completion intimation.
👤
Who Is Affected
Shareholders of Aurobindo Pharma Limited are indirectly affected as a portion of the company's business is now housed within a wholly-owned subsidiary, Auropharm Limited.
🔍
Management Signal
Management is proceeding with the strategic restructuring to house specific business segments within specialized subsidiaries.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Next quarterly results for Aurobindo Pharma for post-transfer performance.
Any future announcements regarding Auropharm Limited's specific financial performance.
Details on how this transfer integrates into Aurobindo Pharma's broader strategic plans.
LOW RISK This is a completed internal business transfer, which carries minimal new risk to the parent company.
💡 Investor Takeaway
Aurobindo Pharma completed the transfer of its domestic branded generic pharmaceutical formulations products business to Auropharm Limited, a wholly-owned subsidiary, effective July 1, 2026. This operational change formalizes the separation of this business segment, previously valued at INR 143.21 Crores.
⚖️ Strengths & Concerns

✅ Positives

  • Completion of the internal business transfer establishes a dedicated entity, Auropharm Limited, for the domestic branded generics segment.
  • The transaction formalizes the operational structure for the domestic branded generic pharmaceutical formulations products business as a going concern.
📅 Company Track Record
Aurobindo Pharma previously intimated the transfer of its domestic branded pharmaceutical formulations business to Auropharm Limited for INR 143.21 Crores on April 6, 2026. The company also completed the acquisition of Lannett Company, Inc., USA on June 29, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What business segment did Aurobindo Pharma transfer?
Aurobindo Pharma transferred its domestic branded generic pharmaceutical formulations products business to Auropharm Limited.
When did the business transfer become effective?
The transfer of the domestic branded generic pharmaceutical formulations products business became effective from July 1, 2026.
To which entity was the business transferred?
The business was transferred to Auropharm Limited (formerly known as Auro Pharma Limited), a wholly-owned subsidiary of Aurobindo Pharma.
What was the nature of the transfer as per the Business Transfer Agreement?
The transfer was as a going concern on a slump sale basis, as per the Business Transfer Agreement mentioned in the April 6, 2026 intimation.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.